Celebrex JRA Indication To Be Evaluated By FDA Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Lack of long-term safety data “poses a special challenge” in weighing risks and benefits, FDA says in briefing documents.
You may also be interested in...
Celebrex Gets Thumbs Up For Kids, But Cmte. Wants Follow-Up
FDA’s Arthritis Advisory Committee urges Pfizer to create an active surveillance program to track potential safety issues from the use of the COX-2 inhibitor for juvenile rheumatoid arthritis.
Celebrex Gets Thumbs Up For Kids, But Cmte. Wants Follow-Up
FDA’s Arthritis Advisory Committee urges Pfizer to create an active surveillance program to track potential safety issues from the use of the COX-2 inhibitor for juvenile rheumatoid arthritis.
Use Of Highly Selective NSAID Comparator In Arcoxia Trials Remains Controversial
Merck’s Arcoxia should not be approved based on a comparison to diclofenac in the MEDAL studies, Cleveland Clinic’s Nissen says.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: